All In Biotech

Drug Trial Radar · NCT06911502

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) Vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy

Last checked: Nov 19, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Jul 28, 2025

Primary completion

Apr 24, 2028

Study completion Jul 31, 2030

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Apr 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.

Conditions

  • Follicular Lymphoma

Interventions

  • GolcadomideDrug

    Specified dose on specified days

  • RituximabDrug

    Specified dose on specified days

  • LenalidomideDrug

    Specified dose on specified days

  • CyclophosphamideDrug

    Specified dose on specified days

  • DoxorubicinDrug

    Specified dose on specified days

  • VincristineDrug

    Specified dose on specified days

  • Prednisone/PrednisoloneDrug

    Specified dose on specified days

  • BendamustineDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS) assessed by Independent Review Adjudication committee (IRAC)Time frame: Up to approximately 32 Months

Locations

160 sites in 21 countries. Site status is shown where the registry gives one.

  • Local Institution - 0225

    Birmingham, Alabama · Not yet recruiting

  • Infirmary Cancer Care

    Mobile, Alabama · Recruiting

  • Alaska Oncology and Hematology

    Anchorage, Alaska · Recruiting

  • Local Institution - 0215

    Little Rock, Arkansas · Not yet recruiting

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Recruiting

  • UCSF Helen Diller Medical Center at Parnassus Heights

    San Francisco, California · Recruiting

  • Local Institution - 0008

    Jacksonville, Florida · Not yet recruiting

  • Local Institution - 0214

    Tampa, Florida · Not yet recruiting

  • Local Institution - 0217

    Tampa, Florida · Not yet recruiting

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital

    Marietta, Georgia · Recruiting

  • Southeastern Regional Medical Center

    Newnan, Georgia · Recruiting

  • Local Institution - 0240

    Arlington Heights, Illinois · Not yet recruiting

  • Local Institution - 0253

    Iowa City, Iowa · Not yet recruiting

  • Local Institution - 0243

    Waukee, Iowa · Not yet recruiting

  • Local Institution - 0216

    Westwood, Kansas · Not yet recruiting

  • Local Institution - 0218

    Lexington, Kentucky · Not yet recruiting

  • Local Institution - 0023

    Baltimore, Maryland · Not yet recruiting

  • Greater Baltimore Medical Center

    Towson, Maryland · Recruiting

  • Local Institution - 0145

    Boston, Massachusetts · Not yet recruiting

  • Local Institution - 0244

    Boston, Massachusetts · Not yet recruiting

  • Local Institution - 0247

    Boston, Massachusetts · Not yet recruiting

  • Hattiesburg Clinic Hematology/Oncology

    Hattiesburg, Mississippi · Recruiting

  • Local Institution - 0144

    Providence, Rhode Island · Not yet recruiting

  • Texas Oncology - Central/South Texas

    Austin, Texas · Recruiting

  • Local Institution - 0212

    Fort Worth, Texas · Not yet recruiting

  • Local Institution - 0230

    San Antonio, Texas · Not yet recruiting

  • Texas Oncology - Northeast Texas

    Tyler, Texas · Recruiting

  • Local Institution - 0238

    Fairfax, Virginia · Not yet recruiting

  • Hematology Oncology Associates of Fredericksburg

    Fredericksburg, Virginia · Recruiting

  • Blue Ridge Cancer Care

    Roanoke, Virginia · Recruiting

  • Local Institution - 0143

    Vancouver, Washington · Not yet recruiting

  • Westmead Hospital

    Westmead, New South Wales, Australia · Recruiting

  • Local Institution - 0132

    Adelaide, South Australia, Australia · Not yet recruiting

  • Local Institution - 0131

    Hobart, Tasmania, Australia · Not yet recruiting

  • Local Institution - 0128

    Heidelberg, Victoria, Australia · Not yet recruiting

  • Cabrini Hospital - Malvern

    Malvern, Victoria, Australia · Recruiting

  • Local Institution - 0127

    Perth, Western Australia, Australia · Not yet recruiting

  • Local Institution - 0224

    Perth, Western Australia, Australia · Withdrawn

  • Local Institution - 0089

    Rio de Janeiro, Brazil · Not yet recruiting

  • Local Institution - 0066

    São Paulo, Brazil · Not yet recruiting

Showing 40 of 160 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.